Floatz logo

Cetuximab

Diffuse Large B-Cell Lymphoma

Genmabmonoclonal_antibodyPhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

41 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Beth Israel Deaconess Medical Center
Phase 4BBB
Cyclophosphamide
Beth Israel Deaconess Medical Center
Phase 4BBB
DEXAMETHASONE
Mwanasha Merrill, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →